Is Retevmo Effective for Lung Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 19, 2022, Alexander Drilon and colleagues from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center published the results of the Phase 1/2 LIBRETTO-001 trial in the "Journal of Clinical Oncology." The study evaluated the efficacy and safety of Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC).
LIBRETTO-001 is a single-arm, open-label Phase 1/2 trial. A total of 316 patients with RET fusion-positive NSCLC were treated with Retevmo. The primary endpoint was objective response rate (ORR), and secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. The study included 69 treatment-naive patients and 247 patients who had previously received platinum-based chemotherapy.
For treatment-naive patients, the primary endpoint ORR was 84%, with a 6% complete response (CR) rate. Secondary endpoints included a median DOR of 20.2 months and a median PFS of 22.0 months.
For patients previously treated with platinum-based chemotherapy, the primary endpoint ORR was 61%, with a 7% CR rate. Secondary endpoints included a median DOR of 28.6 months and a median PFS of 24.9 months.
In patients with central nervous system (CNS) metastases (N=26), the intracranial ORR was 85%, with a 27% CR rate.
Regarding safety, the adverse event profile was consistent with previously reported data, and no new safety signals were identified.
Based on the LIBRETTO-001 results, Alexander Drilon stated that Retevmo demonstrates significant anti-tumor activity in patients with RET fusion-positive NSCLC, regardless of prior treatment, including those with intracranial metastases.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00393
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4